| Mrs Linda K Brown, MD | |
|
12801 Iron Bridge Rd, Suite 100, Chester, VA 23831-1669 | |
| (804) 706-5827 | |
| (804) 706-5819 |
| Full Name | Mrs Linda K Brown |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 30 Years |
| Location | 12801 Iron Bridge Rd, Chester, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780678581 | NPI | - | NPPES |
| H72735 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 0101237588 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cjw Medical Center | Richmond, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| John Randolph Ob/gyn, Llc | 3577580539 | 6 |
News Archive
China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that it will report its unaudited financial results for the fourth fiscal quarter ("4Q FY2008") and fiscal year ended March 31, 2009 ("FY2008") and the first fiscal quarter ("1Q FY2009") ended June 30, 2009 before the U.S. market opens on September 1, 2009. The Company's 2009 fiscal year ends on March 31, 2010.
Researchers at University of California, San Diego School of Medicine have discovered a cell signaling pathway that appears to exert some control over initiation and progression of colorectal cancer, the third leading cause of cancer-related death in the United States. A key protein in the pathway also appears to be predictive of cancer survival rates.
Extracellular polysaccharides play a central role in the survival capabilities of caries-causing bacteria in dental plaque, report researchers from the University of Basel's Preventative Dentistry and Oral Microbiology Clinic and Department of Biomedical Engineering in the journal Plos One.
Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that for the January - May 2009 time period, a significantly higher percentage of hetastarch recipients (75%) underwent a surgical procedure when compared to those receiving albumin/plasma protein fraction (51%).
Giving 10mg per day of the bisphosphate drug alendronate to women after their menopause can help prevent loss of bone mass, reducing their risk of fractures, a Cochrane Review has found.
› Verified 4 days ago
| Entity Name | John Randolph Ob/gyn, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720117559 PECOS PAC ID: 3577580539 Enrollment ID: O20051028000450 |
News Archive
China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that it will report its unaudited financial results for the fourth fiscal quarter ("4Q FY2008") and fiscal year ended March 31, 2009 ("FY2008") and the first fiscal quarter ("1Q FY2009") ended June 30, 2009 before the U.S. market opens on September 1, 2009. The Company's 2009 fiscal year ends on March 31, 2010.
Researchers at University of California, San Diego School of Medicine have discovered a cell signaling pathway that appears to exert some control over initiation and progression of colorectal cancer, the third leading cause of cancer-related death in the United States. A key protein in the pathway also appears to be predictive of cancer survival rates.
Extracellular polysaccharides play a central role in the survival capabilities of caries-causing bacteria in dental plaque, report researchers from the University of Basel's Preventative Dentistry and Oral Microbiology Clinic and Department of Biomedical Engineering in the journal Plos One.
Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that for the January - May 2009 time period, a significantly higher percentage of hetastarch recipients (75%) underwent a surgical procedure when compared to those receiving albumin/plasma protein fraction (51%).
Giving 10mg per day of the bisphosphate drug alendronate to women after their menopause can help prevent loss of bone mass, reducing their risk of fractures, a Cochrane Review has found.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Linda K Brown, MD 12801 Iron Bridge Rd, Suite 100, Chester, VA 23831-1669 Ph: (804) 706-5827 | Mrs Linda K Brown, MD 12801 Iron Bridge Rd, Suite 100, Chester, VA 23831-1669 Ph: (804) 706-5827 |
News Archive
China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that it will report its unaudited financial results for the fourth fiscal quarter ("4Q FY2008") and fiscal year ended March 31, 2009 ("FY2008") and the first fiscal quarter ("1Q FY2009") ended June 30, 2009 before the U.S. market opens on September 1, 2009. The Company's 2009 fiscal year ends on March 31, 2010.
Researchers at University of California, San Diego School of Medicine have discovered a cell signaling pathway that appears to exert some control over initiation and progression of colorectal cancer, the third leading cause of cancer-related death in the United States. A key protein in the pathway also appears to be predictive of cancer survival rates.
Extracellular polysaccharides play a central role in the survival capabilities of caries-causing bacteria in dental plaque, report researchers from the University of Basel's Preventative Dentistry and Oral Microbiology Clinic and Department of Biomedical Engineering in the journal Plos One.
Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that for the January - May 2009 time period, a significantly higher percentage of hetastarch recipients (75%) underwent a surgical procedure when compared to those receiving albumin/plasma protein fraction (51%).
Giving 10mg per day of the bisphosphate drug alendronate to women after their menopause can help prevent loss of bone mass, reducing their risk of fractures, a Cochrane Review has found.
› Verified 4 days ago
Christopher Alfonso Manipula, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 12220 Iron Bridge Rd, Suite A, Chester, VA 23831 Phone: 804-706-5827 Fax: 804-706-5819 |